Are clinical features derived from evidences and experiences outside of Japan applicable to clinical practices in Japan? - Comparisons of results among studies conducted in US, Europe, Asian countries and Japan

Brain and Nerve

Volumn 63, Issue 3, 2011, Pages 247-254

  Kamada, Kyousuke ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Asian populations; Clinical features; Clinical practice in Japan; Levetiracetam; Partial seizures

Indexed keywords

ETIRACETAM; PLACEBO;

ANTICONVULSANT THERAPY; CHINA; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITION; COMPARATIVE STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; EUROPE; EVIDENCE BASED PRACTICE; EXPERIENCE; HUMAN; JAPAN; JAPANESE; KOREA; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SEIZURE; TAIWAN; TREATMENT RESPONSE; UNITED STATES;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EPILEPSIES, PARTIAL; EUROPE; FAR EAST; HUMANS; JAPAN; PIRACETAM; UNITED STATES;

EID: 79953165343     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Crepeau AZ, Treiman DM: Levetiracetam: a comprehensive review. Expert Rev Neurother 10: 159-171, 2010
2. Karceski S, Morrell MJ, Carpenter D: Treatment of epilepsy in adults: expert opinion. Epilepsy Behav 7: S1-S64, 2005 (Pubitemid 41131320)
3. Patsalos PN: Clinical Pharmacokinetics of Levetiracetam. Clin Pharmacokinet 43: 707-724, 2004
4. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A: Population Pharmacokinetics of Levetiracetam in Japanese and Western Adults. Clin Pharmacokinet 46: 503-512, 2007 (Pubitemid 46827859)
5. Zhao Q, Jiang J, Li X, Lu ZS, Hu P: Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Pharmacol 63: 614-617, 2007 (Pubitemid 46632565)
6. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, et al: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236-242, 2000 (Pubitemid 30604624)
7. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P for the European Levetiracetam Study Group: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41: 1179-1186, 2000
8. Ben-Menachem E, Falter U for the European Levetiracetam Study Group: Efficacy and tolerability of levetiracetam 3,000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41: 1276-1283, 2000
9. Wu XY, Hong Z, Wu X, Wu LW, Wang XF, et al: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 50: 398-405, 2009
10. Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, et al: Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47: 72-81, 2006
11. White JR, Walczak TS, Leppik IE, Rarick J, Tran T, et al: Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61: 1218-1221, 2003 (Pubitemid 37377540)
12. Heo K, Lee BI, Yi SD, Huh K, Kim JM, et al: Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure 16: 402-409, 2007
13. Kwan P, Lim SH, Chinvarun Y, Cabral-Lim L, Abdul Aziz Z, et al: Efficacy and safety of levetiracetam as adjunctive therapy in adult patients with uncontrolled partial epilepsy: the Asia SKATE II Study. Epilepsy Behav 18: 100-105, 2010
14. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, et al: The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54: 153-161, 2003 (Pubitemid 36776733)
15. Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I: The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 76: 6-14, 2007 (Pubitemid 47243697)
16. Betts T, Waegemans T, Crawford P: A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000 mg daily and 4,000 mg daily, without titration in patients with refractory epilepsy. Seizure 9: 80-87, 2000 (Pubitemid 30209795)
17. Meencke HJ, Buyle S: Assessment of a dose-response relationship of levetiracetam. Eur J Neurol 13: 942-946, 2006
18. French J, Arrigo C: Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 46: 324-326, 2005 (Pubitemid 40194678)
19. Zhou B, Zhang Q, Tian L, Xiao H, Stefan H, et al: Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 12: 305-310, 2008
20. Cramer JA, Arrigo C, Van Hammée G, Gauer LJ, Cereghino JJ for the N132 Study Group: Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41: 868-874, 2000 (Pubitemid 30439579)
21. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR: A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 4: 124-132, 2003 (Pubitemid 37184583)